Pre-Operative fSRS for Brain Metastases
Improving Outcomes in Patients With Metastatic Cancer to the Brain With Pre-Operative Fractionated Radiosurgery (fSRS): A Pilot Study
This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.
This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.
The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.
This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10075
- Lenox Hill Hospital, Northwell Health
-
Investigatore principale:
- A. Gabriella Wernicke, MD, MS
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient is ≥18 years old.
- Radiographic confirmation of 1-5 brain metastases by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
- The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
- Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
- All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
- Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
- Karnofsky Performance Status (KPS) ≥50 within 14 days prior to registration.
- A negative urine or serum pregnancy test (for individuals of childbearing potential) ≤14 days prior to registration.
- Patient or legally authorized representative provides study-specific informed consent before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.
Exclusion Criteria:
- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.
Note: Prior or current fSRS/SRS to other non-index lesions is allowed.
- Evidence of leptomeningeal disease.
- Any contraindication or inability to undergo MRI with contrast.
- Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.
Note: Chemotherapy and immunotherapy outside of this window are allowed.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Pre-Operative fSRS Followed by Re-Section
This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy. |
Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases. Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Local Freedom from Progression (FFP) within the Resection Cavity
Lasso di tempo: 6, 12, 18, and 24 Months Post-Operative
|
The absence of new nodular contrast enhancement 2 mm or less from the resection cavity. |
6, 12, 18, and 24 Months Post-Operative
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Leptomeningeal Disease (LMD)
Lasso di tempo: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of LMD on brain MRI imaging |
From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
|
Incidence of Radiation Necrosis (RN)
Lasso di tempo: From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of RN on brain MRI imaging |
From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
|
Change in Neurocognitive Function
Lasso di tempo: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Assessed using the Montreal Cognitive Assessment (MoCA) score |
Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
Lasso di tempo: Between Surgery and Post-Operative Visit
|
Comparison of pathological characteristics of resected brain metastasis with the primary tumor |
Between Surgery and Post-Operative Visit
|
|
Correlation of Extent of Surgical Resection with Survival Outcomes
Lasso di tempo: From study registration until 2 years post-operative or death
|
Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS) |
From study registration until 2 years post-operative or death
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Shepard MJ, Sheehan JP. The Choice of Postoperative Stereotactic Radiosurgery After Resection of an Isolated Brain Metastasis. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940. doi: 10.1016/j.ijrobp.2018.05.081. Epub 2019 Oct 24. No abstract available.
- Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4.
- Palmer JD, Perlow HK, Matsui JK, Ho C, Prasad RN, Liu K, Upadhyay R, Klamer B, Wang J, Damante M, Ghose J, Blakaj DM, Beyer S, Grecula J, Arnett A, Thomas E, Chakravarti A, Lonser R, Hardesty D, Prevedello D, Prabhu R, Elder JB, Raval RR. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol. 2022 Sep;159(2):389-395. doi: 10.1007/s11060-022-04073-w. Epub 2022 Jun 25.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Processi patologici
- Neoplasie per sede
- Neoplasie
- Processi neoplastici
- Neoplasie del sistema nervoso
- Neoplasie del sistema nervoso centrale
- Condizioni patologiche, segni e sintomi
- Metastasi neoplastica
- Neoplasie cerebrali
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 26-0403
- 23-004 (Altro identificatore: Northwell Health Cancer Institute)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .